Myriad Settles 2 More Suits Over Cancer Test Patent

Overview


McDermott continues to represent Ambry Genetics Corp. in its patent dispute with Myriad Genetics Inc., which has agreed to drop claims filed in Utah federal court alleging that Ambry and others infringed Myriad’s patents for BRCA cancer gene testing. A Utah federal judge had previously dismissed the lawsuits with prejudice after the parties agreed to drop their claims and counterclaims.